UB Paderborn / Katalog / Suche / in CDI

Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels

Scientific reports, 2020-01, Vol.10 (1), p.223-223, Article 223

2020

Volltextzugriff (PDF)

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

The New England journal of medicine, 2011-11, Vol.365 (18), p.1684-1692

2011

Volltextzugriff (PDF)

Large Intron Inversions in Romanian Patients with Hemophilia A—First Report

Medicina (Kaunas, Lithuania), 2023-10, Vol.59 (10), p.1821

2023

Volltextzugriff (PDF)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

Clinical and applied thrombosis/hemostasis, 2020, Vol.26, p.1076029620950836-1076029620950836

2020

Volltextzugriff (PDF)

Rare within Rare: A Girl with Severe Haemophilia A and Turner Syndrome

Journal of clinical medicine, 2023-11, Vol.12 (23), p.7437

2023

Volltextzugriff (PDF)

Challenges in the Diagnosis and Management of Non-Severe Hemophilia

Journal of clinical medicine, 2022-06, Vol.11 (12), p.3322

2022

Volltextzugriff (PDF)

MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members

Cellular physiology and biochemistry, 2020-10, Vol.54 (5), p.994-1012

2020

Volltextzugriff (PDF)

Lupus anticoagulant in children – a confounding factor in diagnosis and targeted therapy

Revista română de medicină de laborator, 2021-07, Vol.29 (3), p.287-298

2021

Volltextzugriff (PDF)

Mobile Health Technology for the Personalized Therapy of Hemophilia

Frontiers in medicine, 2021-08, Vol.8, p.711973-711973

2021

Volltextzugriff (PDF)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A

Frontiers in medicine, 2021-04, Vol.8, p.654197-654197

2021

Volltextzugriff (PDF)

Minimal invasive oro-dental procedures – recommendations for optimal care in children with haemophilia

Practica medicală (2006), 2018-12, Vol.13 (4), p.267-270

2018

Volltextzugriff (PDF)

Pitfalls in hemostasis exploration, a case report of a girl with Henoch-Schönlein type vasculitis

Revista română de medicină de laborator, 2017-07, Vol.25 (3), p.295-300

2017

Volltextzugriff (PDF)

The impact of immunological and biomolecular investigations on the outcome of children with acute lymphoblastic leukemia - experience of IIIrd Paediatric Clinic Timisoara

Revista română de medicină de laborator, 2018-01, Vol.26 (1), p.77-85

2018

Volltextzugriff (PDF)

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Journal of thrombosis and haemostasis, 2015-03, Vol.13 (3), p.360-369

2015

Volltextzugriff (PDF)

Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.e364-e367

2019

Volltextzugriff (PDF)

RNA sequencing suggests that non‐coding RNAs play a role in the development of acquired haemophilia

Journal of cellular and molecular medicine, 2023-07, Vol.27 (13), p.1790-1796

2023

Volltextzugriff (PDF)

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.1989-1998

2015

Volltextzugriff (PDF)

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.354-360

2016

Volltextzugriff (PDF)

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Journal of clinical immunology, 2011-10, Vol.31 (5), p.752-761, Article 752

2011

Volltextzugriff (PDF)

Surgical comorbidities - a high medical and financial burden for hemophilia care

Revista Medico-Chirurgicala, 2021-06, Vol.125 (2), p.306-314

Serban, P.

2021

Volltextzugriff (PDF)

Joint disease and its medical and socio-economic impact on haemophilia care in Romania

Revista Medico-Chirurgicala, 2021-03, Vol.125 (1), p.154-161

Serban, P.

2021

Volltextzugriff (PDF)

Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors

Revista română de medicină de laborator, 2017-04, Vol.25 (2), p.135-143

2017

Volltextzugriff (PDF)

Fifteen Years of the J Project

Journal of clinical immunology, 2019-05, Vol.39 (4), p.363-369

2019

Volltextzugriff (PDF)

Pharmacoeconomic Analysis of Hemophilia Care in Romania

Processes, 2020-12, Vol.8 (12), p.1676

2020

Volltextzugriff (PDF)

The impact of replacement therapy on dental health in haemophilia

Romanian journal of legal medicine, 2019-06, Vol.27 (2), p.200-204

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

Large Intron Inversions in Romanian Patients with Hemophilia A—First Report

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

Rare within Rare: A Girl with Severe Haemophilia A and Turner Syndrome

Challenges in the Diagnosis and Management of Non-Severe Hemophilia

MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members

Lupus anticoagulant in children – a confounding factor in diagnosis and targeted therapy

Mobile Health Technology for the Personalized Therapy of Hemophilia

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A

Minimal invasive oro-dental procedures – recommendations for optimal care in children with haemophilia

Pitfalls in hemostasis exploration, a case report of a girl with Henoch-Schönlein type vasculitis

The impact of immunological and biomolecular investigations on the outcome of children with acute lymphoblastic leukemia - experience of IIIrd Paediatric Clinic Timisoara

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients

RNA sequencing suggests that non‐coding RNAs play a role in the development of acquired haemophilia

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Surgical comorbidities - a high medical and financial burden for hemophilia care

Joint disease and its medical and socio-economic impact on haemophilia care in Romania

Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors

Fifteen Years of the J Project

Pharmacoeconomic Analysis of Hemophilia Care in Romania

The impact of replacement therapy on dental health in haemophilia

Suchergebnisse filtern